## EMN: Eastman Chemical Company - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_20 0.4% below STRENGTH zone (4.0-10.0%); PEG 3.74 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($57.59)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Eastman Chemical Stock Forecast: Where Analysts See the Stock Going by 2027**
- Source: TIKR.com | 20251203T112123 | Somewhat-Bullish | Relevance: 100%
- Eastman Chemical Company (NYSE: EMN) has faced recent pressure due to weakened demand and pricing softness, but analysts project a potential 31% return by 2027, driven by valuation normalization and improving market conditions. The company's strategic focus on cost efficiency and molecular recycling positions it for recovery despite current cyclical pressures. While near-term growth may be muted, analysts see long-term potential supported by free cash flow generation and alignment with sustainability trends.

**2. Eastman Chemical (EMN): Assessing Value Potential After Recent Share Price Recovery**
- Source: Simply Wall Street | 20251202T233619 | Somewhat-Bullish | Relevance: 100%
- Eastman Chemical's (EMN) shares have seen recent movement, leading to questions about whether the current price reflects its fundamentals. The stock is considered 14.9% undervalued according to Simply Wall St's analysis, with a fair value of $72.76 compared to its last close of $61.95. The article discusses potential growth drivers in sustainable materials and highlights key risks and investment considerations for the company.

**3. Eastman Chemical Co. stock underperforms Tuesday when compared to competitors**
- Source: MarketWatch | 20251202T172800 | Somewhat-Bearish | Relevance: 100%
- Eastman Chemical Co. (EMN) stock declined by 1.55% on Tuesday, closing at $60.99. This underperformance occurred despite a generally positive day for the broader stock market, with both the S&P 500 Index and the Dow Jones Industrial Average posting gains. The decrease marked the second consecutive day of losses for the company's stock.

**4. Eastman Chemical (EMN): Assessing Value Potential After Recent Share Price Recovery**
- Source: Simply Wall Street | 20251202T193238 | Somewhat-Bullish | Relevance: 100%
- This article assesses the value potential of Eastman Chemical (EMN) after a recent share price recovery, noting its 1-year total shareholder return of -37.3%. Despite challenges, the company is estimated to be 14.9% undervalued, with a fair value of $72.76 compared to its current price of $61.95, driven by growth in sustainable materials and stable contracts. Investors are encouraged to consider the potential for recovery and delve into analyst forecasts and identified risks.

**5. JPMorgan Chase & Co. Reduces Stock Position in Eastman Chemical Company $EMN**
- Source: MarketBeat | 20251201T102403 | Neutral | Relevance: 100%
- JPMorgan Chase & Co. significantly reduced its stake in Eastman Chemical Company (NYSE:EMN) by 27.2% in Q2, selling over 313,000 shares but retaining a substantial holding. This divestment follows Eastman Chemical missing its Q3 earnings and revenue estimates and setting conservative FY2025 guidance. Despite analysts trimming price targets, the stock maintains a "Moderate Buy" consensus rating.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Evercore ISI Gr | $70 | $75 | -7% |
| 2025-11-05 | UBS | $73 | $75 | -3% |
| 2025-11-05 | Wells Fargo | $70 | $80 | -12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Evercore ISI Gr | main | In-Line |
| 2025-11-05 | UBS | main | Buy |
| 2025-11-05 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.2%)
- Blackrock Inc.: 7.0% (+0.9%)
- State Street Corpora: 5.0% (+24.3%)
- Capital Research Glo: 3.7% (-1.0%)
- Dimensional Fund Adv: 3.5% (+14.4%)

### Key Risks

1. Valuation risk: PEG 3.7x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 16.8% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.74 signals overvaluation risk, limited margin of safety. Forward P/E 10.0x attractive for 13% earnings growth. Analyst sentiment negative (3 target cuts vs 0 raises). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.3B |
| Beta | 1.25 |
| 52W Range | $56.11 - $103.82 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.74 |
| Forward P/E | 10.0 |
| Current P/E | 11.3 |
| YoY Growth | 13.4% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 1.7% to 0.4% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.83x), long-term trend not supportive. RSI neutral at 53. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.40% (CS: 55) | Neutral |
| RSI_14 | 53.3 | Neutral |
| MACD Histogram | 0.41 | Bullish |
| vs SMA20 | 1.023x | Above |
| vs SMA50 | 1.008x | Above |
| vs SMA200 | 0.832x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $61.57
- **Stop Loss:** $57.59 (6.5% risk)
- **Target:** $65.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 238
- **Position Value:** $14,653.66
- **Portfolio %:** 14.65%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-29 (Est: $0.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.14 | -2.2% |
| 2025Q2 | $1.75 | $1.60 | -8.7% |
| 2025Q1 | $1.89 | $1.91 | +1.2% |
| 2024Q4 | $1.57 | $1.87 | +18.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*